Latest Drug Royalties News

Page 1 of 1

Neuren’s DAYBUE Royalties Climb 16% as Patient Numbers Hit Record High

Neuren Pharmaceuticals reports a 16% rise in Q2 2025 royalties driven by Acadia’s DAYBUE sales growth and expanding patient base in the US. Full-year sales guidance remains strong with European market entry on the horizon.

Victor Sage

7 Aug 2025

Browse the archive

Full archive

Aug 2026 July 2026 June 2026 May 2026 Apr 2026 Mar 2026 Feb 2026 Jan 2026

Top